Interventional Cardiology: Peripheral Vascular Disease Therapeutic Devices
Interventional Cardiology: Peripheral Vascular Disease Therapeutic Devices
$4,750.00
This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for peripheral vascular disease (PVD) therapeutic devices.
Publisher: Meddevicetracker
- Highlights
- Description
- Contents
Topics Covered Include
- An overview of minimally invasive devices for the treatment of PVD, including: angioplasty catheters, atherectomy catheters, CTO crossing devices, thromboembolectomy catheters, and
vascular stents. - Global and country/region-specific market forecasts, including forecasts by product segment.
- Competitive analyses by product segment.
- Discussion of key drivers and limiters impacting the major product segments.
- Primary research with interventional cardiologists from the US, five major EU markets, and Japan focused on how physicians are utilizing these devices and their preferred/most frequently utilized manufacturers.
- A review of emerging technologies which could impact sales of existing devices.
Report Highlights
- Total unit sales for PVD therapeutic devices are steadily increasing due to a number of factors, including: the increasing prevalence of CVD and PVD, advances in CVD diagnostics to better identify candidates for surgery, and demand for minimally invasive interventional therapies to treat patients requiring surgical interventions to manage their conditions.
- In 2017, vascular stents accounted for the majority of PVD therapeutic device sales.
- Vascular stent sales are projected to experience the strongest growth during the forecast period (2017-22) due to the introduction of drug-eluting stents for the treatment of PVD and demand in emerging markets.
- The global market for PVD therapeutic devices is anticipated to increase at a CAGR of 7.2% during the forecast period, reaching approximately $5,876.6m in total product sales by 2022.
- The US was the largest market for PVD therapeutic device sales in 2017. Sales of PVD therapeutic devices to the US accounted for approximately 39.6% of all product sales in 2017.
- Meddevicetracker estimates that the rest of the world (RoW) segment will see the strongest growth throughout the forecast period.
- Angioplasty catheters and vascular stents are the primary therapies for the treatment of PVD, due to the abundance of data supporting the safety and efficacy of these devices in the treatment of PVD.
Overview
Markets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the markets for therapeutic devices for the treatment of peripheral vasclar disease (PVD). Therapeutic devices covered by the scope of this report include:
- angioplasty catheters (POBA, DCB, cutting, and scoring balloon angioplasty catheters)
- vascular stents (bare-metal and drug-eluting stents)
- atherectomy catheters
- thromboembolectomy catheters
- chronic total occlusion crossing devices
The global market for PVD therapeutic devices is anticipated to see moderate, single-digit growth throughout the forecast period covered by this analysis (2017-22). Growth in unit sales is being driven by the increasing prevalence of cardiovascular disease, which is the leading cause of death globally, responsible for over 17 million deaths annually. Primary research querying interventional cardiologists regarding device preferences and utilization was leveraged in the formulation of this report’s forecasts and analyses. Global product sales are projected to expand at a compound annual growth rate (CAGR) of 7.2% during the 2017-22 forecast, increasing from approximately $4,151.3m in 2017 to an estimated $5,876.6m in 2022.
Table of Contents
Executive Summary …………………………………………………………………………………………………… ES‐1
i. Peripheral vascular disease overview……………………………………………………………………..ES‐1
ii. Global peripheral vascular disease therapeutic devices market ………………………………..ES‐1
a. Market drivers and limiters……………………………………………………………………….ES‐3
b. Device segment insights …………………………………………………………………………..ES‐4
c. Technology trends……………………………………………………………………………………ES‐5
d. Market leaders………………………………………………………………………………………..ES‐5
e. Competitive strategies……………………………………………………………………………..ES‐5
f. Emerging competition ………………………………………………………………………………ES‐6
iii. Methodology……………………………………………………………………………………………………..ES‐6
iv. Bibliography ………………………………………………………………………………………………………ES‐8
Exhibit ES‐1: PVD therapeutic devices, global market forecast ($m), 2017‐22 ……………………………ES‐2
Exhibit ES‐2: Global PVD therapeutic devices market, share by country/region, 2017 ………………..ES‐3
Exhibit ES‐3: Drivers and limiters of market growth – vascular access site closure products………..ES‐4
1. Peripheral Vascular Disease Overview…………………………………………………………………………. 1‐1
1.1 Critical limb ischemia …………………………………………………………………………………………. 1‐3
1.2 Aneurysm…………………………………………………………………………………………………………. 1‐3
1.3 Deep vein thrombosis/pulmonary embolism………………………………………………………… 1‐4
1.4 Diagnosis and treatment…………………………………………………………………………………….. 1‐5
1.5 Bibliography ……………………………………………………………………………………………………… 1‐7
Exhibit 1‐1: Estimated prevalence of peripheral artery disease, select countries, 2016 ………………. 1‐2
Exhibit 1‐2: Estimated incident cases of DVT, select countries, 2017 ………………………………………… 1‐4
Exhibit 1‐3: Estimated incident cases of PE, select countries, 2017…………………………………………… 1‐5
2. Peripheral Vascular Disease Therapeutic Products ………………………………………………………… 2‐1
2.1 Angioplasty catheters ………………………………………………………………………………………… 2‐1
2.1.1 Balloon angioplasty products ……………………………………………………………….. 2‐1
2.1.2 Drug‐coated balloon catheter products …………………………………………………. 2‐2
2.1.3 Cutting and scoring balloon catheter products……………………………………….. 2‐3
2.2 Vascular stents………………………………………………………………………………………………….. 2‐3
2.2.1 Bare‐metal stents………………………………………………………………………………… 2‐4
2.2.2 Drug‐eluting stents ……………………………………………………………………………… 2‐5
2.2.3 Bioabsorbable stents and bioresorbable vascular scaffolds………………………. 2‐5
2.3 Atherectomy catheters………………………………………………………………………………………. 2‐6
2.4 Thromboembolectomy catheters………………………………………………………………………… 2‐7
2.5 Chronic total occlusion therapy devices……………………………………………………………….. 2‐9
2.6 Bibliography ……………………………………………………………………………………………… 2‐11
3. Peripheral Vascular Disease Therapeutic Devices Market……………………………………………….. 3‐1
3.1 Global market insights……………………………………………………………………………………….. 3‐1
3.1.1 Market value………………………………………………………………………………………. 3‐2
3.1.2 Technology trends ………………………………………………………………………………. 3‐8
3.1.3 Market drivers and limiters ………………………………………………………………….. 3‐9
3.1.4 PVD therapeutic devices overview ………………………………………………………. 3‐11
3.1.5 Market leaders………………………………………………………………………………….. 3‐15
3.1.6 Competitive strategies……………………………………………………………………….. 3‐15
3.1.7 Emerging competition ……………………………………………………………………….. 3‐16
3.2 Global competitors ………………………………………………………………………………………….. 3‐17
3.2.1 Angioplasty catheters………………………………………………………………………… 3‐17
3.2.2 Vascular stents………………………………………………………………………………….. 3‐18
3.2.3 Atherectomy catheters………………………………………………………………………. 3‐20
3.2.4 Thrombectomy catheters …………………………………………………………………… 3‐20
3.2.5 CTO crossing devices………………………………………………………………………….. 3‐21
3.3 Market forecast……………………………………………………………………………………………….. 3‐22
3.3.1 Market forecast: US …………………………………………………………………………… 3‐22
3.3.2 Market forecast: five major EU markets……………………………………………….. 3‐34
3.3.3 Market forecast: Japan ………………………………………………………………………. 3‐47
3.3.4 Market forecast: Rest of the world………………………………………………………. 3‐59
3.4 Bibliography ……………………………………………………………………………………………………. 3‐69
Exhibit 3‐1: PVD therapeutic devices, global market forecast ($m), 2017‐22……………………………… 3‐2
Exhibit 3‐2: Global PVD therapeutic device market, market forecast ($m), by product segment, 2017‐22 ……………………………………………………………………………….. 3‐4
Exhibit 3‐3: Global PVD therapeutic device sales, share by product segment, 2017 ……………………. 3‐5
Exhibit 3‐4: Global PVD therapeutic devices market, share by country/region, 2017 ………………….. 3‐6
Exhibit 3‐5: Global PVD therapeutic device sales, combined market forecast ($m), by country/region, 2017‐22…………………………………………………………………………………… 3‐7
Exhibit 3‐6: Drivers and limiters of market growth – vascular access site closure products………… 3‐11
Exhibit 3‐7: Estimated average sale price, selected angioplasty catheters, 2017 ………………………. 3‐12
Exhibit 3‐8: Estimated average sale price, selected vascular stents, 2017………………………………… 3‐13
Exhibit 3‐9: Angioplasty catheters market, share by supplier, 2017 ………………………………………… 3‐18
Exhibit 3‐10: Vascular stents market, share by supplier, 2017………………………………………………… 3‐19
Exhibit 3‐11: Atherectomy devices market, share by supplier, 2017 ……………………………………….. 3‐20
Exhibit 3‐12: Thrombectomy devices market, share by supplier, 2017 ……………………………………. 3‐21
Exhibit 3‐13: US PVD therapeutic device sales, estimated market forecast ($m), by product type, 2017‐22………………………………………………………………………………………………… 3‐24
Exhibit 3‐14: US percutaneous transluminal angioplasty, procedure volumes forecast (000s), 2017‐22 ……………………………………………………………………. 3‐25
Exhibit 3‐15: US percutaneous transluminal angioplasty catheter sales, market forecast ($m), 2017‐22 …………………………………………………………………………………… 3‐26
Exhibit 3‐16: US peripheral vascular stent implantation, procedure volumes forecast (000s), 2017‐22…………………………………………………………………………………. 3‐27
Exhibit 3‐17: US peripheral vascular stent sales, market forecast ($m), 2017‐22………………………. 3‐28
Exhibit 3‐18: US peripheral atherectomy, procedure volumes forecast (000s), 2017‐22……………. 3‐29
Exhibit 3‐19: US peripheral atherectomy device sales, market forecast ($m), 2017‐22……………… 3‐30
Exhibit 3‐20: US peripheral thrombectomy, procedure volumes forecast (000s), 2017‐22…………. 3‐31
Exhibit 3‐21: US peripheral thrombectomy sales, market forecast ($m), 2017‐22…………………….. 3‐32
Exhibit 3‐22: US chronic total occlusion, procedure volumes forecast (000s), 2017‐22……………… 3‐33
Exhibit 3‐23: US CTO crossing device sales, market forecast ($m), 2017‐22……………………………… 3‐34
Exhibit 3‐24: 5EU PVD therapeutic device sales, estimated market forecast ($m), by product type, 2017‐22 ……………………………………………………………………………………. 3‐37
Exhibit 3‐25: 5EU percutaneous transluminal angioplasty, procedure volumes forecast (000s), 2017‐22…………………………………………………………………………………. 3‐38
Exhibit 3‐26: 5EU percutaneous transluminal angioplasty catheter sales, market forecast ($m), 2017‐22 …………………………………………………………………………………… 3‐39
Exhibit 3‐27: 5EU peripheral vascular stent implantation, procedure volumes forecast (000s), 2017‐22…………………………………………………………………………………. 3‐40
Exhibit 3‐28: 5EU peripheral vascular stent sales, market forecast ($m), 2017‐22…………………….. 3‐41
Exhibit 3‐29: 5EU peripheral atherectomy, procedure volumes forecast (000s), 2017‐22………….. 3‐42
Exhibit 3‐30: 5EU peripheral atherectomy device sales, market forecast ($m), 2017‐22……………. 3‐43
Exhibit 3‐31: 5EU peripheral thrombectomy, procedure volumes forecast (000s), 2017‐22 ………. 3‐44
Exhibit 3‐32: 5EU peripheral thrombectomy sales, market forecast ($m), 2017‐22…………………… 3‐45
Exhibit 3‐33: 5EU chronic total occlusion, procedure volumes forecast (000s), 2017‐22……………. 3‐46
Exhibit 3‐34: 5EU CTO crossing device sales, market forecast ($m), 2017‐22……………………………. 3‐47
Exhibit 3‐35: Japanese PVD therapeutic device sales, estimated market forecast ($m), by product type, 2017‐22 ……………………………………………………………………………………. 3‐49
Exhibit 3‐36: Japanese percutaneous transluminal angioplasty, procedure volumes forecast (000s), 2017‐22…………………………………………………………………………………. 3‐50
Exhibit 3‐37: Japanese percutaneous transluminal angioplasty catheter sales, market forecast ($m), 2017‐22 …………………………………………………………………………………… 3‐51
Exhibit 3‐38: Japanese peripheral vascular stent implantation, procedure volumes forecast (000s), 2017‐22…………………………………………………………………………………. 3‐52
Exhibit 3‐39: Japanese peripheral vascular stent sales, market forecast ($m), 2017‐22 …………….. 3‐53
Exhibit 3‐40: Japanese peripheral atherectomy, procedure volumes forecast (000s), 2017‐22…… 3‐54
Exhibit 3‐41: Japanese peripheral atherectomy device sales, market forecast ($m), 2017‐22…….. 3‐55
Exhibit 3‐42: Japanese peripheral thrombectomy, procedure volumes forecast (000s), 2017‐22 .. 3‐56
Exhibit 3‐43: Japanese peripheral thrombectomy sales, market forecast ($m), 2017‐22 …………… 3‐57
Exhibit 3‐44: Japanese chronic total occlusion, procedure volumes forecast (000s), 2017‐22…….. 3‐58
Exhibit 3‐45: Japanese CTO crossing device sales, market forecast ($m), 2017‐22 ……………………. 3‐59
Exhibit 3‐46: RoW PVD therapeutic device sales, estimated market forecast ($m), by product type, 2017‐22 ……………………………………………………………………………………. 3‐61
Exhibit 3‐47: RoW percutaneous transluminal angioplasty catheter sales, market forecast ($m), 2017‐22………………………………………………………………………………………………………… 3‐64
Exhibit 3‐48: RoW peripheral vascular stent sales, market forecast ($m), 2017‐22 …………………… 3‐65
Exhibit 3‐49: RoW peripheral atherectomy device sales, market forecast ($m), 2017‐22…………… 3‐66
Exhibit 3‐50: RoW peripheral thrombectomy sales, market forecast ($m), 2017‐22 …………………. 3‐67
Exhibit 3‐51: RoW CTO crossing device sales, market forecast ($m), 2017‐22 ………………………….. 3‐68
Appendix: Company Listing………………………………………………………………………………………………….. A‐1
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the